Re:Search Institution Members

162 Results for Collaborations

Collaborations

Leishmania is a parasite that disfigures or kills two million people every year in the developing world. There may be concerns about the efficacy and safety of current antileishmanial agents. In order to address this high-priority gap, Dr. Dawn Wetzel, Assistant Professor of Pediatrics and Pharmacology at UTSW, has identified a specific class of inhibitors with biological activity against Leishmania parasites. In order to support Dr. Wetzel’s antiparasitic screening efforts, Eisai Co., Ltd., has agreed to share inhibitors from this class of compounds.

GSK will be sharing its Tres Cantos Anti-Malarial Set (TCAMS) compound library with Drs. Audrey Odom John and Paul Hruz at WUSTL for screening for antimalarial drug discovery.

TCAMS, developed as a component of GSK’s research at its Tres Cantos facility, is a diverse set of over 13,500 compounds with activity against blood-stage Plasmodium falciparum, plus associated screening data. GSK shares the TCAMS compounds and data widely to drive antimalarial drug discovery.

Praziquantel was discovered 40 years ago and remains the only available treatment for schistosomiasis, a disease that affects 240 million people globally. Through WIPO Re:Search, investigators from Seattle Children’s Research Institute and the NIAID-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID) are working to solve the crystal structure for Schistosoma HMG-CoA reductase (SmHMGR), a promising drug target. To support these efforts, MSD* scientists developed and shared codon-optimized SmHMGR gene constructs for expressing the SmHMGR protein and solving its crystal structure. With a crystal structure, Dr. Conor Caffrey at the University of California, San Diego plans to carry out rational drug design and optimization of SmHMGR inhibitors.

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA

Buruli ulcer, a bacterial disease found mostly in Central and West Africa, destroys skin and soft tissue, resulting in large necrotic ulcers. Primarily affecting children, the disease causes significant long-term functional disability and permanent deformity unless diagnosed and treated early. In addition to requiring frequent visits to health clinics over a period of several weeks — which is not always practical in remote areas — current medicines can also cause severe side effects such as hearing loss. Professor Fabrice Boyom at University of Yaoundé I aims to develop a safer Buruli ulcer drug that can be
administered over a shorter time frame. Merck KGaA, Darmstadt, Germany is sharing its Mini Library with Professor Boyom for his Buruli ulcer drug discovery program.

Chagas disease, human African trypanosomiasis, and leishmaniasis are neglected tropical diseases that collectively affect millions of people worldwide. Improved treatments for all three diseases are greatly needed. Merck KGaA, Darmstadt, Germany will provide GRIDD investigator Dr. Vicky Avery with its Mini Library to screen for Chagas disease, human African trypanosomiasis, and leishmaniasis drug discovery.

Merck KGaA, Darmstadt, Germany’s Mini Library is a collection of drug-like former Biopharma research and development compounds and their derivatives. The compounds cover a wide range of molecular targets, including enzymes, hormone and neurotransmitter receptors, transporters, and ion channels.

Johnson & Johnson will be sharing a phenotypic screening library with Dr. Lawal Bilbis at UDUS for screening for antimalarial drug discovery.

170 Results for Assets

Assets

The invention pertains to full-length polypeptides and fragments from naturally occurring Merozoite Surface Protein 1 (MSP-1; a protein expressed in later stage erythrocytic malaria) including vectors having encoding nucleic acids thereof that are useful as DNA vaccines. The intent was that the MSP-1 proteins expressed through these vectors would generate protective immune responses against subsequent infection by Plasmodium falciparum, the pathogen responsible for malaria.
Synthetic genes for malarial proteins and methods of use Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.
Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins EBPs. The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.
Wucheria bancrofti, the major causative organism of lymphatic filariasis, is a filarial nematode estimated to infect 120 million people worldwide. The World Health Organization has targeted this disease for eradication. Current technology fails to recognize prepatent infections so there is a strong need for this technology in eradication efforts. This immunologically based assay detects Wuchereria bancrofti infection with no cross reactivity with other closely related filariae.
NIH Internal Reference no E-006-1990/0-US-01; US Patent Application no 07/470,692; and E-006-1990/0-US-02; US Patent Application no 08/462,616 Chloroquine an approved drug and the most commonly used antimalarial agent and analogs such as primaquine have been shown to inhibit infectious HIV-1 production and thus its spread in infected individuals. Inhibition may occur via interference with the terminal glycosylation of the viral glycoproteins, which results in the production of noninfectious virus.
This application relates to immunogenic conjugates which elicit an immune response to Plasmodium proteins. This application claims conjugates that include at least one Plasmodium sexual stage surface protein covalently linked to at least one Plasmodium circumsporozoite protein (CSP) or an immunogenic portion of a CSP. Also claimed in the application are conjugates that include at least one sexual stage surface protein covalently linked to at least one immunogenic repeat derived from a Plasmodium CSP. The inventors' data shows that these conjugates also induced long-lasting antibody responses to each of their components, i.e. the vaccine candidates showed both transmission blocking activity and antibodies to the CSP (or portion thereof).